Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Sensorion

< Previous 1 2 3 4 Next >
Sensorion Publishes Results of Combined Shareholders’ General Meeting Resolutions
From Sensorion
Via Business Wire
Sensorion Announces its Participation in Upcoming Investor Conferences in June 2024
From Sensorion
Via Business Wire
Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 29, 2024
From Sensorion
Via Business Wire
Sensorion Announces its Participation in the American Society of Cell and Gene Therapy (ASGCT) Annual Meeting
From Sensorion
Via Business Wire
Sensorion Announces its Participation in the Van Lanschot Kempen's Life Sciences Conference
From Sensorion
Via Business Wire
Sensorion Announces a €15 Million Financing, Extending Cash Runway Until the End of 2025
From Sensorion
Via Business Wire
Sensorion Announces the Availability of Its Letter to Shareholders
From Sensorion
Via Business Wire
Sensorion Announces its Participation in the Annual Bioprocessing Summit Europe
From Sensorion
Via Business Wire
Sensorion Announces the Availability of its Financial Report for 2023
From Sensorion
Via Business Wire
Sensorion Reports Full-Year 2023 Financial Results and Business Update
From Sensorion
Via Business Wire
Sensorion Announces it Has Met Primary Endpoint for SENS-401 Phase 2a Clinical Study for Residual Hearing Preservation
From Sensorion
Via Business Wire
Sensorion Will Host a Webcast on March 14, 2024, to Announce its 2023 Annual Financial Results
From Sensorion
Via Business Wire
Sensorion Announces its Participation in the Leerink Partners Global Biopharma Conference
From Sensorion
Via Business Wire
Sensorion Announces a €50.5 Million Financing With Participation From New and Existing US and European Healthcare Specialist Investors
From Sensorion
Via Business Wire
Sensorion Announces the Completion of Patient Inclusion in Phase 2a Clinical Trial of SENS-401 for Residual Hearing Preservation After Cochlear Implantation
From Sensorion
Via Business Wire
Sensorion Announces its Participation in the Association for Research in Otolaryngology ARO 47th Annual Midwinter Meeting
From Sensorion
Via Business Wire
Sensorion Appoints Dr. Federico Mingozzi as Non-Executive Director to the Board of Directors
From Sensorion
Via Business Wire
Sensorion Announces Approval to Initiate Lead Gene Therapy Candidate SENS-501 (OTOF-GT) into a Phase 1/2 Clinical Trial in some European Countries
From Sensorion
Via Business Wire
Sensorion Announces Partnership With the Institut Pasteur to Accelerate Gene Therapy Programs Targeting Hearing Disorders Has Been Extended for Five Years
From Sensorion
Via Business Wire
Sensorion Publishes Results of Combined General Meeting Resolutions
From Sensorion
Via Business Wire
Sensorion Provides an Update on NOTOXIS, its Proof of Concept Phase 2a Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity (CIO)
From Sensorion
Via Business Wire
Sensorion Appoints CMC Expert Bernd Schmidt as New Chief Technical Officer
From Sensorion
Via Business Wire
Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of December 20, 2023
From Sensorion
Via Business Wire
Sensorion Announces Its Attendance at the 42nd Annual J.P. Morgan Healthcare Meeting in San Francisco
From Sensorion
Via Business Wire
Sensorion to Participate in the Jefferies London Healthcare Conference and McDermott Will & Emery’s Life Sciences Symposium
From Sensorion
Via Business Wire
Sensorion Will Present At The European Society Of Gene & Cell Therapy (ESGCT) Conference
From Sensorion
Via Business Wire
Sensorion Announces the Availability of Its Financial Report for the 1st Half of 2023
From Sensorion
Via Business Wire
Sensorion Announces Webconference on September 25, 2023, and its Participation in Upcoming Investor Conferences in October 2023
From Sensorion
Via Business Wire
Sensorion Reports 2023 First Half Results
From Sensorion
Via Business Wire
Sensorion Submits Clinical Trial Application for OTOF-GT, its Lead Gene Therapy Candidate, in Europe
From Sensorion
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS